Table 4.

Treatment-emergent adverse events and serious adverse events (safety analysis set)

	Keverprazan (n = 180)	Lansoprazole (n = 178)	P Value
TEAEs, patients (%)	104 (57.8)	105 (59.0)	0.8309
Mild	92 (51.1)	101 (56.7)
Moderate	11 (6.1)	4 (2.3)
Severe	1 (0.6)	0 (0.0)	1.0000
Study drug related	46 (25.6)	58 (32.6)	0.1627
Leading to study drug discontinuation	3 (1.7)	2 (1.1)	1.0000
Leading to study drug discontinuation (study drug related)	1 (0.6)	1 (0.6)	1.0000
Serious adverse events	3 (1.7)	1 (0.06)	0.6229
Serious adverse events (study drug related)	1 (0.6)	0	1.0000

TEAEs, treatment-emergent adverse events.